{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:21:21Z","timestamp":1780579281952,"version":"3.54.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T00:00:00Z","timestamp":1622073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cannabis Res"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>US states have been adopting their own medical cannabis laws since 1996. There is substantial variability in the medical cannabis programs between states, and these differences have not been thoroughly investigated in the literature. The objective of the study was to compare medical cannabis patient characteristics across five states to identify differences potentially caused by differing policies surrounding condition eligibility.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We conducted secondary analyses following a retrospective study of a registry database with data from 33 medical cannabis evaluation clinics in the US, owned and operated by CB2 Insights. This study narrowed the dataset to include patients from five states with the largest samples: Massachusetts (<jats:italic>n<\/jats:italic> = 27,892), Colorado (<jats:italic>n<\/jats:italic> = 16,434), Maine (<jats:italic>n<\/jats:italic> = 4591), Connecticut (<jats:italic>n<\/jats:italic> = 2643), and Maryland (<jats:italic>n<\/jats:italic> = 2403) to conduct an in-depth study of the characteristics of patients accessing medical cannabis in these states, including analysis of variance to compare average ages and number of conditions and chi-squared tests to compare proportions of patient characteristics between states.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Average ages varied between the states, with the youngest average in Connecticut (42.2) and the oldest in Massachusetts (47.0). Males represented approximately 60% of the patients with data on gender in each state. The majority of patients in each state had cannabis experience prior to seeking medical certification. Primary medical conditions varied for each state, with chronic pain, anxiety, and back and neck problems topping the list in varying orders for Massachusetts, Maine, and Maryland. Colorado had 78.7% of patients report chronic pain as their primary condition, and 70.4% of patients in Connecticut reported post-traumatic stress disorder as their primary medical condition.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>This study demonstrated the significant impact that policy has on patients\u2019 access to medical cannabis in Massachusetts, Colorado, Maine, Connecticut, and Maryland utilizing real-world data. It highlights how qualifications differ between the five states and brings into question the routes through which patients in states with stricter regulations surrounding eligible conditions choose to seek treatment with cannabis. These patients may turn to alternative treatments, or to the illicit or recreational cannabis markets, where permitted.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s42238-021-00075-z","type":"journal-article","created":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T17:51:36Z","timestamp":1622137896000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Comparing medical cannabis use in 5 US states: a retrospective database study"],"prefix":"10.1186","volume":"3","author":[{"given":"V. Kishan","family":"Mahabir","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Vannabouathong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jamil J.","family":"Merchant","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6332-7754","authenticated-orcid":false,"given":"Alisha L.","family":"Garibaldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,5,27]]},"reference":[{"key":"75_CR1","unstructured":"128th Maine Legislature. An act to amend Maine\u2019s medical marijuana law. http:\/\/legislature.maine.gov\/legis\/bills\/getPDF.asp?paper=HP1060&item=1&snum=128. Accessed 11 Aug 2020."},{"key":"75_CR2","unstructured":"2018 NSDUH Detailed Tables | CBHSQ Data. https:\/\/www.samhsa.gov\/data\/report\/2018-nsduh-detailed-tables. Accessed 27 Mar 2020."},{"key":"75_CR3","doi-asserted-by":"publisher","unstructured":"Alsherbiny MA, Li CG. Medicinal cannabis-potential drug interactions. Med (Basel, Switzerland). 2018;6(1). https:\/\/doi.org\/10.3390\/medicines6010003.","DOI":"10.3390\/medicines6010003"},{"issue":"2","key":"75_CR4","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1377\/hlthaff.2018.05266","volume":"38","author":"KF Boehnke","year":"2019","unstructured":"Boehnke KF, Gangopadhyay S, Clauw DJ, Haffajee RL. Qualifying conditions of medical cannabis license holders in the United States. Health Aff. 2019a;38(2):295\u2013302. https:\/\/doi.org\/10.1377\/hlthaff.2018.05266.","journal-title":"Health Aff"},{"issue":"6","key":"75_CR5","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1016\/j.jpain.2016.03.002","volume":"17","author":"KF Boehnke","year":"2016","unstructured":"Boehnke KF, Litinas E, Clauw DJ. Medical cannabis use is associated with decreased opiate medication use in a retrospective cross-sectional survey of patients with chronic pain. J Pain. 2016;17(6):739\u201344. https:\/\/doi.org\/10.1016\/j.jpain.2016.03.002.","journal-title":"J Pain"},{"issue":"7","key":"75_CR6","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.jpain.2019.01.010","volume":"20","author":"KF Boehnke","year":"2019","unstructured":"Boehnke KF, Scott JR, Litinas E, Sisley S, Williams DA, Clauw DJ. Pills to pot: observational analyses of cannabis substitution among medical cannabis users with chronic pain. J Pain. 2019b;20(7):830\u201341. https:\/\/doi.org\/10.1016\/j.jpain.2019.01.010.","journal-title":"J Pain"},{"issue":"10","key":"75_CR7","doi-asserted-by":"publisher","first-page":"1414","DOI":"10.1016\/j.addbeh.2014.05.022","volume":"39","author":"KM Bohnert","year":"2014","unstructured":"Bohnert KM, Perron BE, Ashrafioun L, Kleinberg F, Jannausch M, Ilgen MA. Positive posttraumatic stress disorder screens among first-time medical cannabis patients: prevalence and association with other substance use. Addict Behav. 2014;39(10):1414\u20137. https:\/\/doi.org\/10.1016\/j.addbeh.2014.05.022.","journal-title":"Addict Behav"},{"key":"75_CR8","unstructured":"Bureau UC. U.S. Median Household Income Up in 2018 From 2017. https:\/\/www.census.gov\/library\/stories\/2019\/09\/us-median-household-income-up-in-2018-from-2017.html. Accessed 25 Mar 2020."},{"issue":"1","key":"75_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1177\/0022042616678607","volume":"47","author":"C Cambron","year":"2017","unstructured":"Cambron C, Guttmannova K, Fleming CB. State and national contexts in evaluating cannabis laws: a case study of Washington state. J Drug Issues. 2017;47(1):74\u201390. https:\/\/doi.org\/10.1177\/0022042616678607.","journal-title":"J Drug Issues"},{"key":"75_CR10","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ypmed.2017.07.008","volume":"104","author":"H Carliner","year":"2017","unstructured":"Carliner H, Brown QL, Sarvet AL, Hasin DS. Cannabis use, attitudes, and legal status in the U.S.: a review. Prev Med (Baltim). 2017;104:13\u201323. https:\/\/doi.org\/10.1016\/j.ypmed.2017.07.008.","journal-title":"Prev Med (Baltim)"},{"issue":"2","key":"75_CR11","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1001\/jamapsychiatry.2019.3254","volume":"77","author":"M Cerd\u00e1","year":"2020","unstructured":"Cerd\u00e1 M, Mauro C, Hamilton A, Levy NS, Santaella-Tenorio J, Hasin D, et al. Association between recreational marijuana legalization in the United States and changes in marijuana use and cannabis use disorder from 2008 to 2016. JAMA Psychiatry. 2020;77(2):165\u201371. https:\/\/doi.org\/10.1001\/jamapsychiatry.2019.3254.","journal-title":"JAMA Psychiatry"},{"issue":"2","key":"75_CR12","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1001\/jamapediatrics.2016.3624","volume":"171","author":"M Cerd\u00e1","year":"2017","unstructured":"Cerd\u00e1 M, Wall M, Feng T, Keyes KM, Sarvet A, Schulenberg J, et al. Association of state recreational marijuana laws with adolescent marijuana use. JAMA Pediatr. 2017;171(2):142\u20139. https:\/\/doi.org\/10.1001\/jamapediatrics.2016.3624.","journal-title":"JAMA Pediatr"},{"issue":"1-3","key":"75_CR13","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.drugalcdep.2011.06.011","volume":"120","author":"M Cerd\u00e1","year":"2011","unstructured":"Cerd\u00e1 M, Wall M, Keyes KM, Galea S, Hasin D. Medical marijuana laws in 50 states: investigating the relationship between state legalization of medical marijuana and marijuana use, abuse and dependence. Drug Alcohol Depend. 2011;120(1-3):22\u20137. https:\/\/doi.org\/10.1016\/j.drugalcdep.2011.06.011.","journal-title":"Drug Alcohol Depend"},{"key":"75_CR14","unstructured":"Colorado - Official State Web Portal. Qualifying medical conditions Medical Marijuana Registry. https:\/\/cdphe.colorado.gov\/apply-colorado-medical-marijuana-card. Published 2019. Accessed 11 Aug 2020."},{"key":"75_CR15","unstructured":"Connecticut State Department of Consumer Protection. Qualification Requirements. https:\/\/portal.ct.gov\/DCP\/Medical-Marijuana-Program\/Qualification-Requirements. Published 2020. Accessed 11 Aug 2020."},{"key":"75_CR16","unstructured":"DISA Global Solutions. Map of marijuana legality by state. Retrieved from URL https:\/\/disa.com\/map-of-marijuana-legality-by-state. 2019."},{"issue":"2","key":"75_CR17","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1089\/can.2018.0036","volume":"4","author":"DT Eurich","year":"2019","unstructured":"Eurich DT, Hanlon JG, Boisvenue JJ, Meng H, Dyck JRB. A description of the medical cannabis use in Ontario, Canada. Cannabis Cannabinoid Res. 2019;4(2):131\u20135. https:\/\/doi.org\/10.1089\/can.2018.0036.","journal-title":"Cannabis Cannabinoid Res"},{"key":"75_CR18","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.drugalcdep.2015.11.015","volume":"159","author":"BJ Fairman","year":"2016","unstructured":"Fairman BJ. Trends in registered medical marijuana participation across 13 US states and District of Columbia. Drug Alcohol Depend. 2016;159:72\u20139. https:\/\/doi.org\/10.1016\/j.drugalcdep.2015.11.015.","journal-title":"Drug Alcohol Depend"},{"key":"75_CR19","unstructured":"FDA Regulation of Cannabis and Cannabis-Derived Products, Including Cannabidiol (CBD). U.S. Food and Drug Administration. https:\/\/www.fda.gov\/news-events\/public-health-focus\/fda-regulation-cannabis-and-cannabis-derived-products-including-cannabidiol-cbd. Accessed 1 Feb 2020."},{"key":"75_CR20","doi-asserted-by":"publisher","unstructured":"Ghaffarzadegan N, Ebrahimvandi A, Jalali MS. A dynamic model of post-traumatic stress disorder for military personnel and veterans. 2016;11(10):e0161405. https:\/\/doi.org\/10.1371\/journal.pone.0161405.","DOI":"10.1371\/journal.pone.0161405"},{"issue":"3","key":"75_CR21","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.drugpo.2006.10.001","volume":"18","author":"DM Gorman","year":"2007","unstructured":"Gorman DM, Huber JC. Do medical cannabis laws encourage cannabis use? Int J Drug Policy. 2007;18(3):160\u20137. https:\/\/doi.org\/10.1016\/j.drugpo.2006.10.001.","journal-title":"Int J Drug Policy"},{"key":"75_CR22","unstructured":"Guzman GG. American Community Survey Briefs. www.census.gov\/programs. Accessed 6 Apr 2020."},{"key":"75_CR23","unstructured":"Legislatures NC of S. State medical marijuana laws. https:\/\/www.ncsl.org\/research\/health\/state-medical-marijuana-laws.aspx. 2020."},{"issue":"5","key":"75_CR24","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1503\/jpn.190136","volume":"44","author":"M Leyton","year":"2019","unstructured":"Leyton M. Cannabis legalization: did we make a mistake? Update 2019. J Psychiatry Neurosci. 2019;44(5):291\u20133. https:\/\/doi.org\/10.1503\/jpn.190136.","journal-title":"J Psychiatry Neurosci"},{"issue":"1","key":"75_CR25","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1186\/s12954-019-0278-6","volume":"16","author":"P Lucas","year":"2019","unstructured":"Lucas P, Baron EP, Jikomes N. Medical cannabis patterns of use and substitution for opioids & other pharmaceutical drugs, alcohol, tobacco, and illicit substances; results from a cross-sectional survey of authorized patients. Harm Reduct J. 2019;16(1):9. https:\/\/doi.org\/10.1186\/s12954-019-0278-6.","journal-title":"Harm Reduct J"},{"issue":"1","key":"75_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s42238-020-00038-w","volume":"2","author":"VK Mahabir","year":"2020","unstructured":"Mahabir VK, Merchant JJ, Smith C, Garibaldi A. Medical cannabis use in the United States: a retrospective database study. J Cannabis Res. 2020;2(1):32. https:\/\/doi.org\/10.1186\/s42238-020-00038-w.","journal-title":"J Cannabis Res"},{"key":"75_CR27","unstructured":"Marijuana Decriminalization & Its Impact on Use - NORML - Working to Reform Marijuana Laws. https:\/\/norml.org\/aboutmarijuana\/item\/marijuana-decriminalization-its-impact-on-use-2. Accessed 9 Apr 2020."},{"key":"75_CR28","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1016\/j.yebeh.2016.11.021","volume":"70","author":"A Mead","year":"2017","unstructured":"Mead A. The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law. Epilepsy Behav. 2017;70:288\u201391. https:\/\/doi.org\/10.1016\/j.yebeh.2016.11.021.","journal-title":"Epilepsy Behav"},{"key":"75_CR29","unstructured":"Medical Marijuana Patient Numbers. https:\/\/www.mpp.org\/issues\/medical-marijuana\/state-by-state-medical-marijuana-laws\/medical-marijuana-patient-numbers\/. Accessed 5 Jan 2021."},{"key":"75_CR30","unstructured":"Natalie M. LaPride - Maryland Medical Cannabis Commission. Patients - who is eligible to register as a patient. https:\/\/mmcc.maryland.gov\/pages\/patients.aspx. Accessed 11 Aug 2020."},{"issue":"1","key":"75_CR31","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1146\/annurev-clinpsy-032816-045128","volume":"13","author":"RL Pacula","year":"2017","unstructured":"Pacula RL, Smart R. Medical marijuana and marijuana legalization. Annu Rev Clin Psychol. 2017;13(1):397\u2013419. https:\/\/doi.org\/10.1146\/annurev-clinpsy-032816-045128.","journal-title":"Annu Rev Clin Psychol"},{"issue":"2","key":"75_CR32","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/s0163-7258(97)82001-3","volume":"74","author":"RG Pertwee","year":"1997","unstructured":"Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol Ther. 1997;74(2):129\u201380. https:\/\/doi.org\/10.1016\/s0163-7258(97)82001-3.","journal-title":"Pharmacol Ther"},{"issue":"4","key":"75_CR33","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1124\/pr.110.003004","volume":"62","author":"RG Pertwee","year":"2010","unstructured":"Pertwee RG, Howlett AC, Abood ME, Alexander SPH, di Marzo V, Elphick MR, et al. International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB(1) and CB(2). Pharmacol Rev. 2010;62(4):588\u2013631. https:\/\/doi.org\/10.1124\/pr.110.003004.","journal-title":"Pharmacol Rev"},{"key":"75_CR34","doi-asserted-by":"publisher","DOI":"10.1097\/j.pain.0000000000000899","volume-title":"Chronic pain patients\u2019 perspectives of medical cannabis","author":"BJ Piper","year":"2017","unstructured":"Piper BJ, Beals ML, Abess AT, et al. Chronic pain patients\u2019 perspectives of medical cannabis; 2017a. https:\/\/doi.org\/10.1097\/j.pain.0000000000000899."},{"issue":"5","key":"75_CR35","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1177\/0269881117699616","volume":"31","author":"BJ Piper","year":"2017","unstructured":"Piper BJ, Dekeuster RM, Beals ML, et al. Substitution of medical cannabis for pharmaceutical agents for pain, anxiety, and sleep. J Psychopharmacol. 2017b;31(5):569\u201375. https:\/\/doi.org\/10.1177\/0269881117699616.","journal-title":"J Psychopharmacol"},{"issue":"1","key":"75_CR36","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/1533210107301834","volume":"12","author":"A Reiman","year":"2007","unstructured":"Reiman A. Medical cannabis patients: patient profiles and health care utilization patterns. Complement Health Pract Rev. 2007;12(1):31\u201350. https:\/\/doi.org\/10.1177\/1533210107301834.","journal-title":"Complement Health Pract Rev"},{"issue":"1","key":"75_CR37","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1089\/can.2016.0007","volume":"1","author":"M Sexton","year":"2016","unstructured":"Sexton M, Cuttler C, Finnell JS, Mischley LK. A cross-sectional survey of medical cannabis users: patterns of use and perceived efficacy. Cannabis Cannabinoid Res. 2016;1(1):131\u20138. https:\/\/doi.org\/10.1089\/can.2016.0007.","journal-title":"Cannabis Cannabinoid Res"},{"key":"75_CR38","doi-asserted-by":"publisher","unstructured":"Shannon S, Lewis N, Lee H, Hughes S. Cannabidiol in anxiety and sleep: a large case series. Perm J. 2019;23(18-041). https:\/\/doi.org\/10.7812\/TPP\/18-041.","DOI":"10.7812\/TPP\/18-041"},{"key":"75_CR39","unstructured":"The 191st General Court of The Commonwealth of Massachusetts. Chapter 369 - An act for the humanitarian medical use of marijuana. https:\/\/malegislature.gov\/Laws\/SessionLaws\/Acts\/2012\/Chapter369. Published 2012. Accessed 11 Aug 2020."},{"key":"75_CR40","unstructured":"U.S. Census Bureau QuickFacts: United States. https:\/\/www.census.gov\/quickfacts\/fact\/table\/CT,CO,MD,ME,MA,US\/PST045218. Accessed 9 Apr 2020."},{"key":"75_CR41","unstructured":"US Income Statistics - Current Census Data for Zip Codes. https:\/\/www.incomebyzipcode.com\/. Accessed 27 Mar 2020."},{"key":"75_CR42","unstructured":"VA and Marijuana \u2013 what veterans need to know - Public Health. https:\/\/www.publichealth.va.gov\/marijuana.asp. Accessed 22 Apr 2020."}],"container-title":["Journal of Cannabis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-021-00075-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s42238-021-00075-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s42238-021-00075-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,27]],"date-time":"2021-05-27T17:53:31Z","timestamp":1622138011000},"score":1,"resource":{"primary":{"URL":"https:\/\/jcannabisresearch.biomedcentral.com\/articles\/10.1186\/s42238-021-00075-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,27]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["75"],"URL":"https:\/\/doi.org\/10.1186\/s42238-021-00075-z","relation":{},"ISSN":["2522-5782"],"issn-type":[{"value":"2522-5782","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,27]]},"assertion":[{"value":"21 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This research initiative was submitted for IRB review and determined to be exempt from IRB oversight by the Advarra IRB (Pro00042652) as this study had minimal risk, the data exports were void of patient identifiers, and it did not require direct patient contact.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests aside from being employees of CB2 Insights. All authors contributed to the manuscript as part of an internally guided project. CB2 Insights owns the data, and the authors are all employees of CB2 Insights. No external companies had input on the content of the manuscript, and all data were analyzed in an unbiased fashion. Apart from the authors, CB2 Insights did not play any role in the conduct or analysis of the study, the writing of the manuscript, or the decision to publish.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"15"}}